With a number of GLP-1 medications in Phase 2 trials, we believe that the winning formula to stand out in a crowded landscape will be to combine medication with advanced behavior change to drive differentiated outcomes, while proving it with Phase 4 studies
This warning also includes concerns about hypercalcemia
Retatrutide is Eli Lilly's investigational triple-receptor agonist - one weekly injection that acts on GLP-1, GIP, and glucagon receptors at once to cut appetite, improve insulin signaling, and raise energy use
The answer significantly impacts long-term metabolic health and physical function
Is the shipping container rated for the expected transit time and ambient temperature conditions along the route
What pricing and reimbursement risks (e.g., VBP, biosimilar entry) could impact revenue forecasts after 2026